Alvotech Announces Increase in Number of Own Shares

Rhea-AI Summary

Alvotech (NASDAQ: ALVO) increased share capital by USD 125,000 through issuance of 12,500,000 ordinary shares at USD 5.20 per share to its subsidiary Alvotech Manco ehf.

The subsidiary's holding rises to 16,254,005 shares (4.7%); total issued shares increased from 334,038,147 to 346,538,147. Outstanding shares remain 330,284,142. The increase supports settlement of a prior stock lending facility and the company's obligations for warrants, convertibles, and employee programs.

Key Figures

Share capital increase: USD 125,000 New shares issued: 12,500,000 shares Subscription price: USD 5.2 per share +4 more

7 metrics

Share capital increase USD 125,000 Increase in company share capital via new ordinary shares

New shares issued 12,500,000 shares Ordinary shares subscribed by subsidiary

Subscription price USD 5.2 per share Price paid by subsidiary for newly issued shares

Subsidiary holdings 16,254,005 shares Treasury shares held, equal to 4.7% of issued shares

Total issued shares 346,538,147 shares Increased from 334,038,147 after capital change

Outstanding shares 330,284,142 shares Outstanding share count unchanged after transaction

Treasury share stake 4.7% of issued shares Proportion of issued shares held by subsidiary as treasury

Market Reality Check

Price: $5.20 Vol: Volume 550,652 is 1.74x t...

high vol

$5.20 Last Close

Volume Volume 550,652 is 1.74x the 20-day average of 316,314, indicating elevated trading interest ahead of this capital move. high

Technical At $5.20, ALVO trades below its 200-day MA of $7.61 and about 60% under the 52-week high of $13.08.

Peers on Argus

ALVO is modestly higher while close peers show mixed moves (e.g., BHC +2.84%, SU...

ALVO is modestly higher while close peers show mixed moves (e.g., BHC +2.84%, SUPN -0.45%, ANIP -0.57%), suggesting a stock-specific reaction to the treasury share adjustment rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Clinical study results	Positive	-2.0%	Pivotal PK study for Entyvio biosimilar met all primary endpoints.
Feb 02	Commercial agreements	Positive	-0.9%	Supply and commercialization deals with Sandoz in Canada and ANZ.
Jan 29	Patent settlement	Positive	+2.5%	Global licensing and settlement for Eylea biosimilar enabling market entry.
Jan 07	Insider filing correction	Neutral	+1.5%	Corrected disclosure of closely associated person share transactions.
Jan 06	Insider transactions	Neutral	-6.5%	Disclosure of large share purchases by ATP Holdings ehf.

Pattern Detected

Recent positive operational news has not consistently translated into positive next-day moves, with several constructive updates followed by flat or negative reactions.

Recent Company History

Over the past few months, Alvotech has reported multiple positive business developments, including a pivotal PK study meeting endpoints for an Entyvio biosimilar and new supply and commercialization agreements with Sandoz. It also secured a global settlement for its Eylea biosimilar and disclosed significant manager-related share transactions. Despite these milestones, price reactions have been mixed, with some positive announcements followed by declines, indicating that investors have responded cautiously to otherwise constructive news.

Market Pulse Summary

This announcement details a technical share capital increase of 12,500,000 new shares, subscribed by...

Analysis

This announcement details a technical share capital increase of 12,500,000 new shares, subscribed by a subsidiary and held as treasury shares, leaving outstanding shares unchanged at 330,284,142. It replenishes shares used in a lending facility tied to convertible bonds, supporting future obligations such as warrants and share-based compensation. Investors may track how these treasury shares are deployed alongside recent financing and operational milestones.

Key Terms

treasury shares, convertible bonds, warrants

3 terms

treasury shares financial

"The shares held by the subsidiary are treated as treasury shares without voting rights"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

convertible bonds financial

"stock lending facility to the buyers of Convertible Bonds issued by the Company"

A convertible bond is a loan a company issues that pays regular interest and can be exchanged for a fixed number of the company’s shares under specified terms. It matters to investors because it combines the steady income and lower downside risk of a bond with the upside potential of owning stock—like holding a ticket that can be cashed for equity if the share price rises—affecting returns, risk, and shareholder dilution.

warrants financial

"commitments related to various financial obligations, including warrants, convertible financial instruments"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

AI-generated analysis. Not financial advice.

REYKJAVIK, ICELAND (February 11, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has increased the Company´s share capital by an amount of one hundred and twenty-five thousand (USD 125,000) by issuing twelve million and five-hundred thousand (12,500,000) ordinary shares. The Company’s subsidiary, Alvotech Manco ehf. (the “subsidiary”), has subscribed to all of the newly issued shares for a price of USD 5.2 per share. The shares held by the subsidiary are treated as treasury shares without voting rights or dividend entitlement.

Following the above-mentioned transaction, the subsidiary will hold 16,254,005 shares in the Company, or 4.7% of issued shares, and the number of total issued shares has increased from 334,038,147 to 346,538,147 shares. The number of outstanding shares, consisting of all shares not held as treasury shares by the subsidiary, is unchanged at 330,284,142 shares.

On December 17, 2025, the Company announced that it had provided a stock lending facility to the buyers of Convertible Bonds issued by the Company, for the purpose of facilitating the Convertible Bond investors' hedging activities. The share capital increase is intended to meet the reduction in the number of treasury shares resulting from settlement of the above-mentioned lending of ordinary shares, allowing the Company to continue holding a sufficient number of shares to fulfill the Company’s commitments related to various financial obligations, including warrants, convertible financial instruments, and share-based employee compensation.

CONTACT INFORMATION – INVESTOR RELATIONS
Balaji Prasad, Chief Strategy Officer
Patrik Ling, VP Investor Relations Scandinavia (SE)
Benedikt Stefansson, VP Investor Relations and Global Communications (IS)
alvotech.ir@alvotech.com

About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars, to Humira® (adalimumab), Stelara® (ustekinumab), Eylea® (aflibercept), Simponi® (golimumab) and Prolia®/Xgeva® (denosumab) are already approved and marketed in global markets. Alvotech’s current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, respiratory disease, hematological disorders and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit www.alvotech.com.

FAQ

Why did Alvotech (ALVO) increase its share capital on February 11, 2026?

The company increased share capital to restore treasury share levels needed to meet obligations. According to the company, the issuance supports settlement of a prior stock lending facility and ensures availability for warrants, convertibles, and employee compensation.

How many shares did Alvotech (ALVO) issue and at what price on February 11, 2026?

Alvotech issued 12,500,000 ordinary shares at USD 5.20 per share. According to the company, this raised share capital by USD 125,000 and the shares were subscribed by its subsidiary Alvotech Manco ehf.

What is the effect on Alvotech's (ALVO) total issued and outstanding shares after the increase?

Total issued shares rose to 346,538,147, while outstanding shares remain 330,284,142. According to the company, the subsidiary holds treasury shares and voting/dividend rights are not applicable to those treasury shares.

How much of Alvotech (ALVO) will the subsidiary hold after the transaction and what percent does it represent?

The subsidiary will hold 16,254,005 shares, representing 4.7% of issued shares. According to the company, these shares are treated as treasury shares without voting rights or dividend entitlement.

Does the share issuance dilute Alvotech (ALVO) outstanding shares available to investors?

Outstanding shares remained unchanged at 330,284,142, so investor-held outstanding shares were not increased. According to the company, the issuance was to replenish treasury shares after stock lending settlements rather than expand publicly tradable shares.